Yes, it's hard to see how Yahoo! could have so completely wrecked the message boards. Posts seem to be picked randomly, edited randomly, and put it in random order. There is no reference to current issues and developments. And, although most of our conversations have been deleted, we have been awarded nicknames and cute little monograms. Anyway, it's been nice annoying you, but you won't have bearofbleecker to kick around anymore.
IRWD was being heavily shorted in recent sessions, apparently as a bet on SGYP IBS-C data. It didn't help the shorts when the Mizuho analyst raised her price target on IRWD today.
Well, since I'm posting here, I can obviously "circumvent" the new system which Yahoo! has cooked up. However, making it more challenging to access their stock forums would seem to be stupid. Fewer posters = fewer posts = fewer eyeballs = less advertising revenue.
Aisan pretty well ruined this message board and the Yahoo! Software nitwits gave it the coup de grace. If I log onto Yahoo! Finance on my PC, I am automatically directed to the redesigned page. Rather than the traditional message board, there is a tab labeled "conversations". Here they have reorganized the old posts according to some bizarre scheme. The long tedious autobiographical post by nitabosco leads off the list, followed by some threads from months ago. My own incisive critiques are buried under this detritus. This is obviously a fatal blow to my finances, since I will be deprived of the 50 cent fee I receive for my posts.
Looks like a lot of hedging against IBS-C results. My own guess is that they will be satisfactory and that this will take the stock up above 4 again. Then, after a decent interval of a day or two, they will announce a secondary under 4.
I ask again: Where is the evidence that plecanatide is superior in any way to linaclotide? The panel basically did a rigorous statistical analysis of the trials data and decided that there was no basis for the assumption that in terms of efficacy or incidence of diarrhea, plecanatide had any advantage.
Well, Ram's ph properties put him in a league of his own: ranked # 6,338 of 9,309 "overall experts", #2798 out of 4,305 analysts. Why should you accept those puny gains implied by his $15 price target for SGYP, when you can do much better by following his other pharma tips? For example, on Feb 22, he initiated VRX with a "buy" rating and a price target of $150. In March, as it was collapsing, he reiterated his "buy" rating and lowered the price target to $118. In April, he reiterated his "buy" rating and lowered the price target to $110. Five days ago, he once again reiterated his "buy", lowering his price target to $90 - still a 290% gain over today's close.
If you want a real hot tip from RAJ, dip your toe into Bio-Blast (ORPN). He initiated it in January with a "buy" rating and a 12-month price target of $25. He has just reiterated his "buy" with a price target of 19. If it gets there, you will make 1,058% on your investment. Guess it hasn't been doing that well.
Or, for something more conservative, grab a chunk of PLX, with a price target which implies a 446% gain. Or SRNE, on which he reiterated his "buy" rating on June 24 with a price target of $40. He just lowered that to price target to $30, and when it gets there, you will make 365% on your investment!
Perhaps you are thinking, ""Okay, this guy is not too good at picking pharma stocks." But that's all he does! And he consistently picks duck eggs. If you doubt this, see if you can find a single winner among his picks. Makes you wonder how bad you have to be to be ranked # 3,000 out of 4,305 analysts.
There are two prescription drugs for both CIC and IBS-C; the older one, Amitiza, and the newer one, Linzess. Amitiza is being replaced by Linzess since the latter works better and does not have nausea as a common side effect. If plecanatide had such a clearcut point of superiority over Linzess, there would be more interest in acquiring it. However, in spite of those here who argue that plecanatide causes significantly less diarrhea, a panel of gastroenterologists has decided otherwise. In the absence of new evidence, plecanatide cannot be marketed with a claim of "less diarrhea". Therefore, why should it be marketed at all?
PS Despite the frequent attacks on "these people", I am the only poster here who actually questions the blithe assumptions so prevalent here. (e.g. The stock is worth $8 -10 a share, but only they know this.) Asian is just a pest. Trumpeting his 6,000 share position or challenging serious longs to post their positions after hours is pathetic; I don't understand why anyone would dignify his posts by responding to them.
Itsahorserace, I think you're about even here but are seriously overinvested in SGYP. Sell half. There are no retail shorts. In fact, there is a much larger retail short interest in IRWD.
As I've posted before, I dumped almost all of m IRWD stock on the failed short raid, then reupped around $10. My yearend price target was $12.50. The only poster on the IRWD board is stupid stu, a short. I don't feel it necessary to engage with him.
As a matter of fact, it's impossible for a retail investor to short this stock. The market makers, I think, were shorting it at 3.52, and Paulson took control of the stock from there and left them stranded. I am not emotional - I have been slightly long the stock at a couple of points and never short. I watch it with interest and no financial stake whatsoever.
Your only purpose here is to annoy. Your price predictions have been consistently wrong. You are an embarrassment to bashers everywhere.
Take your pick: (1) The company is at least $2 billion short of what it would take to launch plecanatide; (2) There are no bidders; (3) Aside from Paulson -the genius who loaded up on VRX at 190 and then doubled down - there is no interest; (4) The stock has been diluted about 80% since the beginning of 2015, ...
Or, just observe events which suggest this is a scam: (1)At the end of 2015, the company announces that, although they have suspended trials on dolcanatide to conserve cash, their operating losses have ballooned due to "increased executive compensation"; (2) After a couple of false starts, they announce that the conversion of a convertible note below the conversion price is a wonderful thing since it will save them a lot of money in interest payments ("Good news, honey! The bank just cancelled our credit line!"); (3) The CFO, who was obviously embarrassed by this release, quits. (4.) Release of pathetic 24 patient unblinded one month trial on dolcanatide (must have cost them $50,000); (5) Poor old Paulson signs on for another 30 million shares at $3; etc. etc. Just mentioning any of this will bring the old believers swarming out of the crevices of the reef.
Right. Any commercial which even implied any superiority in terms of side effects wouldn't even make it to the air.
Yes, the amazing insights of the contributors here have correctly outed me as a low level drug rep, a paid tool of mysterious HFT's or hedge funds, a child molestor, a "trapped short" (haven't heard that one for a long time, actually) , an alternate id of whoever, an Ironwood insider, etc. etc.
PPS: Can you name a single drug, prescription or otc, which doesn't have "multiple side effects per label"? Are you suggesting that, upon approval, plecanatide will be the only drug in existence without any side effects?
Congratulations on your modest silence during your recent windfall. You didn't even post once on the CPXX board during the buyout.
PS As impressed as I am by your "stint as an Investment Broker", one wonders why it didn't eventuate in a career.